Breast Cancer Advisor: Telli - Cancer Therapy Advisor

Breast Cancer Advisor: Telli

Chapter 2

Frontline Treatments for Patients With Metastatic Breast Cancer

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the frontline treatment of patients with metastatic breast cancer. One important phase 3 trial presented at 2016 SABCS tested the efficacy of fulvestrant against that anastrozole among patients with advanced ER-positive, HER2-negative metastatic breast cancer, though other treatment options are emerging.

Chapter 3

ER-positive, HER2-negative Breast Cancer: A Changing Landscape

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses how treatment is changing for patients with ER-positive, HER2-negative disease. Dr Telli notes different factors to consider before choosing a treatment combination for a specific patient, especially for patients whose disease is deemed to be high-risk.

Chapter 4

Triple-negative Breast Cancer: Clinical Insights

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the treatment of patients with triple-negative breast cancer. While there are no fully U.S. Food and Drug Administration (FDA)-approved targeted therapies in this disease setting, there is a great deal of emerging research in this area.

Next hm-playlist in Breast Cancer